Authors and Disclosures
Noelle V. Frey, MD1, Pamela A. Shaw, PhD2, Elizabeth O. Hexner, MD1, Edward Pequignot, MS2, Saar Gill, MD, PhD1, Selina M. Luger, MD1, James K. Mangan, MD, PhD1, Alison W. Loren, MD1, Alexander E. Perl, MD1, Shannon L. Maude, MD, PhD3, Stephan A. Grupp, MD, PhD3, Nirav N. Shah, MD4, Joan Gilmore, BS5, Simon F. Lacey, PhD5, Jos J. Melenhorst, PhD5, Bruce L. Levine, PhD5, Carl H. June, MD5 and David L. Porter, MD1
1Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
3Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA
4Medical College of Wisconsin, Milwaukee, WI
5Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA
Corresponding Author
Noelle V. Frey, MD, Hospital of the University of Pennsylvania, 2 PCAM South, 3400 Civic Center Blvd, Philadelphia, PA 19104; e-mail: noelle.frey@uphs.upenn.edu.
Authors' Disclosures of Potential Conflicts of Interest and Data Availability Statement
Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JCO.19.01892.
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/journal/jco/site/ifc.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Noelle V. Frey
Consulting or Advisory Role: Novartis, Kite Pharma, Gilead
Research Funding: Novartis
Pamela A. Shaw
Patents, Royalties, Other Intellectual Property: Patent owned by the University of Pennsylvania currently licensed to Novartis for an algorithm that predicts severe cytokine release syndrome for chimeric antigen receptor T-cell 19 therapy; receive 10% of the licensing fees
Elizabeth O. Hexner
Research Funding: Blueprint Medicines (Inst), Tmunity Therapeutics (Inst)
Edward Pequignot
Patents, Royalties, Other Intellectual Property: As part of the University of Pennsylvania's role in the US Food and Drug Administration approval of chimeric antigen receptor T-cell (CAR-T) therapy and for my part as an employee of the University of Pennsylvania involved in its research in CAR-T; have received royalties of approximately $300 over the past 2 years
Saar Gill
Stock and Other Ownership Interests: Carisma Therapeutics
Honoraria: Fate Therapeutics, Sensei Biotherapeutics, Aro Biotherapeutics
Research Funding: Novartis (Inst)
Patents, Royalties, Other Intellectual Property: Patents for chimeric antigen receptor T cells for acute myeloid leukemia
Selina M. Luger
Honoraria: Pfizer, Daiichi Sankyo, Agios
Research Funding: Cyclacel (Inst), ARIAD (Inst), Onconova Therapeutics (Inst), Biosight (Inst), Roche (Inst), Genentech (Inst), Kura (Inst), Celgene (Inst)
Travel, Accommodations, Expenses: Hemedicus, PER
James K. Mangan
Consulting or Advisory Role: Agios
Alexander E. Perl
Honoraria: Agios, Actinium Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Newlink Genetics, Takeda Pharmaceuticals, AbbVie
Consulting or Advisory Role: Arog, Astellas Pharma, Actinium Pharmaceuticals, Daiichi Sankyo, AbbVie
Research Funding: Actinium Pharmaceuticals (Inst), Astellas Pharma (Inst), Bayer AG (Inst), BioMed Valley Discoveries (Inst), Daiichi Sankyo (Inst), Fujifilm (Inst), Novartis (Inst)
Travel, Accommodations, Expenses: Agios, AbbVie, Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Newlink Genetics, Takeda Pharmaceuticals, Arog
Shannon L. Maude
Consulting or Advisory Role: Novartis, Kite Pharma
Travel, Accommodations, Expenses: Novartis, Kite Pharma
Stephan A. Grupp
Consulting or Advisory Role: Novartis, Jazz Pharmaceuticals, Janssen Pharmaceuticals, Cellular Biomedicine Group, TCR2 Therapeutics, Humanigen, Roche, Vertex, Adaptimmune
Research Funding: Novartis, Kite Pharma, Gilead, SERVIER
Nirav N. Shah
Stock and Other Ownership Interests: Exelixis, Oncosec, Geron, Cidara Therapeutics, Cell Vault
Consulting or Advisory Role: Jazz Pharmaceuticals, Kite Pharma, Incyte, Juno Therapeutics, Celgene
Research Funding: Miltenyi Biotec
Travel, Accommodations, Expenses: Miltenyi Biotec
Simon F. Lacey
Research Funding: Novartis (Inst), Tmunity (Inst)
Patents, Royalties, Other Intellectual Property: Patents and intellectual property related to chimeric antigen receptor T-cell technology licensed to Novartis (Inst)
Jos J. Melenhorst
Consulting or Advisory Role: Shanghai Unicar Therapy, Simcere of America, IASO Biotherapeutics
Research Funding: Novartis (Inst), Incyte (Inst)
Patents, Royalties, Other Intellectual Property: Dr. Melenhorst is a patent inventor for CTL019
Bruce L. Levine
Stock and Other Ownership Interests: Tmunity Therapeutics
Honoraria: Novartis, Terumo, Sysmex, Draper, Astrazeneca
Consulting or Advisory Role: Brammer Bio, Avectas, CRC Oncology, Cure Genetics, Ori Biotech, Vycellix
Research Funding: Novartis, Tmunity Therapeutics
Patents, Royalties, Other Intellectual Property: Intellectual property and patents in the field of cell and gene therapy
Travel, Accommodations, Expenses: GE Healthcare, BrammerBio, Avectas, CRC Oncology
Carl H. June
Stock and Other Ownership Interests: Celldex, Tmunity Therapeutics, Cabaletta, Carisma Therapeutics, Cytosen
Honoraria: Novartis, Pfizer, Johnson & Johnson
Consulting or Advisory Role: Celldex, Viracta Therapeutics, Cabaletta, Carisma Therapeutics, Kiadis Pharma, WIRB-Copernicus Group, Janssen Oncology Research Funding: Novartis, Tmunity Therapeutics
Patents, Royalties, Other Intellectual Property: Intellectual property licensed to Novartis, royalties paid to the University of Pennsylvania; Office of Naval Research, intellectual property and patent royalties; intellectual property licensed to Tmunity Therapeutics (Inst)
David L. Porter
Employment: Genentech (I), Roche (I)
Stock and Other Ownership Interests: Genentech (I), Roche (I)
Consulting or Advisory Role: Novartis, Kite Pharma, Incyte, Gerson Lehrman Group, Bellicum Pharmaceuticals, Glenmark
Research Funding: Novartis
Patents, Royalties, Other Intellectual Property: Dr. Porter is a patent inventor for CTL019
Travel, Accommodations, Expenses: Kite Pharma, Novartis
Other Relationship: National Marrow Donor Program, American Board of Internal Medicine
No other potential conflicts of interest were reported.
Author Contributions
Conception and design: Noelle V. Frey, Edward Pequignot, Saar Gill, Shannon L. Maude, Stephan A. Grupp, Bruce L. Levine, Carl H. June, David L. Porter
Administrative support: Joan Gilmore
Provision of study material or patients: Saar Gill, Selina M. Luger, Alison W. Loren, Alexander E. Perl, Joan Gilmore, Bruce L. Levine
Collection and assembly of data: Noelle V. Frey, Elizabeth O. Hexner, Edward Pequignot, Selina M. Luger, Alison W. Loren, Alexander E. Perl, Joan Gilmore, Simon F. Lacey, Jos J. Melenhorst, Bruce L. Levine
Data analysis and interpretation: Noelle V. Frey, Pamela A. Shaw, Elizabeth O. Hexner, Edward Pequignot, Saar Gill, James K. Mangan, Alison W. Loren, Alexander E. Perl, Stephan A. Grupp, Nirav N. Shah, Simon F. Lacey, Jos J. Melenhorst, Bruce L. Levine, David L. Porter
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
Comments